Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Rosetta Genomics introduces New NGS-based assay to detect somatic mutations

Published 05 August 2016

Rosetta Genomics has expanded its molecular diagnostics test portfolio with the introduction of OncoGxSelect next generation sequencing (NGS)-based test.

The new NGS-based test has been developed to identify somatic mutations frequently found in cancers, helping to take therapeutic decisions related to targeted cancer therapies.

Featuring Admera Health’s NGS technology, the OncoGxSelect is said to interrogate 12 genes implicated in lung cancer types, including ALK, BRAF, EGFR, ERBB2, KIT, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET and ROS1.

It can also be used for other tumor types based on significant mutations found in various cancers such as thyroid cancer.

According to Rosetta, OncoGxSelect targets the genes included in nationally accepted clinical guidelines for molecular testing.

Rosetta Genomics president and CEO Kenneth Berlin said: “The commercial launch of this advanced test provides a more comprehensive set of actionable information for the oncologists and pathologists we serve, and adds to a comprehensive lung-specific menu that assists in answering the most difficult clinical questions clinicians face when treating these patients.

“The OncoGxSelect test adds to the growing number of services we offer, and further establishes Rosetta Genomics as a leader in delivering personalized diagnostic testing.”

Admera president and CEO Dr Guanghui Hu said: “The development of this OncoGxSelect panel and our continued relationship with Rosetta Genomics will increase patient access to cutting edge sequencing diagnostics, advancing precision medicine by providing oncologists with a tool to guide targeted therapy treatment decisions.”